Biden Warns: China Could "Eat Our Lunch" When it Comes to Lithium
Pres. Biden recently warned about China's dominance when it comes to lithium demand, stating, "if we don't get moving, they're going to eat our lunch." One junior mining company in South America is looking to become a strong link in the lithium supply chain due to a monster acquisition.
Get the full scoop on this investment opportunity

OPT Insider Trading (Opthea)

Insider Ownership Percentage: N/A
Insider Buying (Last 12 Months): A$0.00
Insider Selling (Last 12 Months): A$0.00

Opthea Insider Trading History Chart

This chart shows the insider buying and selling history at Opthea by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Opthea Share Price & Price History

Current Price: A$0.00
Price Change: +0.30 (1.20%)
As of 05/13/2020 01:00 AM ET

This chart shows the closing price history over time for OPT up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
All Electric Commitment From GM, Volkswagen, Could Put Lithium Stock In A Supercycle
More automakers are pledging to go "fully electric" by 2035. NOW is the perfect time to get in on the "EV Revolution." And the best way to potentially do that, is to skip over the overvalued electric vehicle stocks...
Look At This Under-The-Radar Lithium Company

Opthea Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/11/2021Megan BaldwinInsiderIssued1,600,000A$1.21A$1,936,000.00
3/4/2021Michael SistenichInsiderExercise712,919A$0.48A$342,201.12
4/4/2019Megan BaldwinInsiderSell667,000A$0.66A$440,220.00
3/18/2019Megan BaldwinInsiderIssued3,000,000A$0.75A$2,250,000.00
See Full Table
Insider Trading at Opthea?
Sign-up to receive InsiderTrades.com's daily insider buying and selling report for Opthea and related companies.

SEC Filings (Institutional Ownership Changes) for Opthea (ASX:OPT)

Opthea Limited, a biotechnology company, develops and commercializes therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. Its lead molecule is OPT-302, a soluble form of VEGFR-3 for the treatment of wet age-related macular degeneration and diabetic macular edema. The company was formerly known as Circadian Technologies Limited and changed its name to Opthea Limited in December 2015. Opthea Limited was incorporated in 1984 and is based in South Yarra, Australia.
Read More on Opthea

Today's Range

Now: N/A

50 Day Range

MA: N/A

52 Week Range

Now: N/A

Volume

504,572 shs

Average Volume

N/A

Market Capitalization

N/A

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Who are the company insiders with the largest holdings of Opthea?

Opthea's top insider investors include:
  1. Megan Baldwin (Insider)
  2. Michael Sistenich (Insider)
Biden Warns: China Could "Eat Our Lunch" When it Comes to Lithium
Pres. Biden recently warned about China's dominance when it comes to lithium demand, stating, "if we don't get moving, they're going to eat our lunch." One junior mining company in South America is looking to become a strong link in the lithium supply chain due to a monster acquisition.
Get the full scoop on this investment opportunity